Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lexeo Therapeutics
Biotech
Lexeo acquires Mantle for $8M, adding Friedreich ataxia assets
Lexeo has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million while locking in three strategic collaborations.
Will Maddox
Sep 22, 2026 9:58am
Cardiff Oncology churns C-suite—Chutes & Ladders
Jan 30, 2026 8:30am
Lexeo, J&J team up on heart pump tech for gene therapy delivery
Jan 8, 2026 9:30am
Lexeo laid off 15% in April to focus on cardiac gene therapies
May 12, 2025 8:30am
Lexeo locks in pivotal trial plan as gene therapy data accrue
Apr 7, 2025 9:37am
Lexeo links gene therapy to improvements in rare heart disease
Jul 15, 2024 9:46am
